Natco Pharma Ltd.

Natco Pharma is currently trading at Rs. 907.90, up by 16.85 points or 1.89% from its previous closing of Rs. 891.05 on the BSE.

The scrip opened at Rs. 880.35 and has touched a high and low of Rs. 917.95 and Rs. 880.35 respectively. So far 10276 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1188.95 on 24-May-2021 and a 52 week low of Rs. 771.00 on 19-Feb-2021.

Last one week high and low of the scrip stood at Rs. 917.95 and Rs. 871.25 respectively. The current market cap of the company is Rs. 16592.74 crore.

The promoters holding in the company stood at 48.87%, while Institutions and Non-Institutions held 29.94% and 21.19% respectively.

Natco Pharma’s marketing partner Breckenridge Pharmaceutical, Inc., US has launched the 10 mg strength of Everolimus Tablets (generic for Afinitor) in the US market. The U.S. Food and Drug Administration previously granted final approval of this Abbreviated New Drug Application.

According to industry sales data, the 10 mg strength of Afinitor generated annual sales of $392 million during the twelve months ending July 2021. Breckenridge previously launched Everolimus tablets in 2.5 mg, 5 mg and 7.5 mg strengths during the first quarter of 2021 in the US market.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.